Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in Severe Japanese Cedar Pollinosis (Phase III, 12-week, randomized, double-blind, placebo-controlled)
2017-002154-36Phase 3
- Sponsor
- Novartis
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing Omalizumab with Placebo (2 arms). Primary endpoint: Mean nasal symptom score.
02
Drugs
omalizumab
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on 2017-002154-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002154-36.